KSE - Delayed Quote KRW

Daewoong Pharmaceutical Co., Ltd (069620.KS)

127,200.00

+400.00

(+0.32%)

At close: January 3 at 3:30:30 PM GMT+9

CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts

CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered with CGBIO to host the International Spine Endoscopy Training Course. The event welcomed 12 medical professionals from nine countries, including Mexico, Switzerland, and India. Led by Professor Jin-Sung Kim (also known as Luke) of Seoul St. Mary's Hospital, The Catholic University of Korea — a world-renowned expert in minimally invasive and endoscopic spine surgery — the

PR Newswire 4 days ago

069620.KQ

069620.KS
+0.32%
Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

Daewoong Pharmaceutical has captured the attention of global aesthetic medicine professionals with its innovative botulinum toxin treatment techniques.

PR Newswire 30 days ago

069620.KQ

069620.KS
+0.32%
Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest pharmaceutical and biotech exhibition—held in Milan, Italy. In addition, Daewoong will continue to expand the global reach of its innovative new drugs, Fexuprazan and Enavogliflozin.

PR Newswire 2 months ago

069620.KQ

069620.KS
+0.32%
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant step towards commercialization by demonstrating positive safety data from the Phase 2 clinical trial.

PR Newswire 5 months ago

069620.KQ

069620.KS
+0.32%
Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results

CGBio, a leading medical device company, announced a significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes, "Novosis" and "Excelos Inject," which have been published in the 'Journal of Clinical Medicine'. These results not only highlight the efficacy of the products but also demonstrate their potential for entry into the U.S. healthcare market.

PR Newswire 7 months ago

069620.KS
+0.32%
Daewoong Pharmaceutical Announces 2023 Financial Results

Daewoong Pharmaceutical (KRX: 069620.KS), a global pharmaceutical company located in Seoul, announced its marvelous financial results for 2023.

PR Newswire 10 months ago

069620.KS
+0.32%
Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Daewoong Pharmaceutical's Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis (IPF), a rare and debilitating disease. This first-in-class PRS inhibitor has recently received 'Orphan Drug Designation (ODD)' from the European Medicines Agency (EMA), adding to its earlier designation by the U.S. FDA for both IPF and systemic sclerosis.

PR Newswire 11 months ago

069620.KS
+0.32%

Performance Overview

Return	069620.KS	KOSPI Composite Index
YTD	+0.63%	+1.77%
1-Year	+8.26%	-6.34%
3-Year	-13.72%	-17.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daewoong Pharmaceutical Co., Ltd (069620.KS)

CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results

Daewoong Pharmaceutical Announces 2023 Financial Results

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Performance Overview